Anti-acetylcholine receptor antibody (AChR-Ab) titers and the AChR-Ab rates of change correlated with myasthenia gravis ...
Recently approved treatments for generalized myasthenia gravis (gMG), including complement and neonatal Fc receptor (FcRn) ...
Heightened focus on delays in diagnosing generalized myasthenia gravis (gMG) follows the promise of better results for some patients with newer treatments that include complement inhibitors and ...
Heading into 2025, the chief item on argenx’s agenda is the FDA’s April 10 target action date to decide on the approval of a ...
COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission ...
Sugammadex (Bridion; Merck) is a small-molecule oligosaccharide, also known as a modified gamma cyclodextin, that was ...
Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...
A woman from Ellsworth is navigating life with a rare neuromuscular disease. Tina Bruning learned of her diagnosis of Generalized Myasthenia Gravis or gMG in May of 2021.
BofA analyst Jason Gerberry lowered the firm’s price target on Immunovant (IMVT) to $38 from $45 and keeps a Buy rating on the shares. The firm ...
In the EU, rozanolixizumab is indicated as an add-on to standard therapy for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or ...